Moradi A, Kodali A, Okoye C, et al. A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors? Cureus. 2023;15(7): e42071.

PubMed  PubMed Central  Google Scholar 

Irabor OC, Nelson N, Shah Y, Niazi MK, Poiset S, Storozynsky E, et al. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Front Oncol. 2022;12: 940127.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martínez-Méndez D, Villarreal C, Mendoza L, Huerta L. An Integrative Network Modeling Approach to T CD4 Cell Activation. Front Physiol. 2020;11:380.

Article  PubMed  PubMed Central  Google Scholar 

Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47(5):765–79. https://doi.org/10.1002/eji.201646875.

Article  CAS  PubMed  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park J, Kwon M, Shin EC. Immune checkpoint inhibitors for cancer treatment. Arch Pharm Res. 2016;39:1577–87.

Article  CAS  PubMed  Google Scholar 

Alturki NA. Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment. J Clin Med. 2023;12(13):4301.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–14.

Article  CAS  PubMed  Google Scholar 

Zander H, Müller-Egert S, Zwiewka M, Groß S, van Zandbergen G, Engelbergs J. Checkpointinhibitoren in der Tumortherapie [Checkpoint inhibitors for cancer therapy]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020;63(11):1322–1330.

Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res. 2021;128:1780–801.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res. 2004;95(12):1140–53.

Article  CAS  PubMed  Google Scholar 

Thuny F, Naidoo J, Neilan TG. Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J. 2022;43(42):4458–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tajiri K, Sekine I. Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients. Jpn J Clin Oncol. 2022;52(7):659–64. https://doi.org/10.1093/jjco/hyac041.

Article  PubMed  Google Scholar 

Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, Ciardiello F, Pane F, Au L, Emmerich M, Plummer C, Gulati G, Ramalingam S, Cardinale D, Brezden-Masley C, Iakobishvili Z, Thavendiranathan P, Santoro C, Bergler-Klein J, Keramida K, de Boer RA, Maack C, Lutgens E, Rassaf T, Fradley MG, Moslehi J, Yang EH, De Keulenaer G, Ameri P, Bax J, Neilan TG, Herrmann J, Mbakwem AC, Mirabel M, Skouri H, Hirsch E, Cohen-Solal A, Sverdlov AL, van der Meer P, Asteggiano R, Barac A, Ky B, Lenihan D, Dent S, Seferovic P, Coats AJS, Metra M, Rosano G, Suter T, Lopez-Fernandez T, Lyon AR. Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2024.

Gergely TG, Drobni ZD, Sayour NV, Ferdinandy P, Varga ZV. Basic Res Cardiol. 2024. https://doi.org/10.1007/s00395-024-01068-8.

Article  PubMed  Google Scholar 

Ronen D, Bsoul A, Lotem M, Abedat S, Yarkoni M, Amir O, Asleh R. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Vaccines (Basel). 2022;10(4):540.

Article  CAS  PubMed  Google Scholar 

Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, Bechter O, et al. Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors. J Clin Oncol. 2022;40(29):3430–8.

Article  CAS  PubMed  Google Scholar 

Zheng Y, Chen Z, Song W, Xu Y, Zhao Z, Sun Y, et al. Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study. Cancer Med. 2024;13(10): e7233.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naqash AR, Moey MYY, Cherie Tan XW, Laharwal M, Hill V, Moka N, et al. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. J Clin Oncol. 2022;40(29):3439–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;10:1739–47.

Article  Google Scholar 

Suzuki Y, Kaneko H, Tamura Y, Okada A, Fujiu K, Michihata N, et al. Cardiovascular events after the initiation of immune checkpoint inhibitors. Heliyon. 2023;9(5): e16373.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou YW, Zhu YJ, Wang MN, Xie Y, Chen CY, Zhang T, Xia F, Ding ZY, Liu JY. Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management. Front Pharmacol. 2019;10:1350.

Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58.

Article  CAS  PubMed  Google Scholar 

Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55.

Article  PubMed  PubMed Central  Google Scholar 

Flynn MJ, Larkin JMG. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. Expert Opin Pharmacother. 2017;18:1477–90.

Article  CAS  PubMed  Google Scholar 

Martinez-Calle N, Rodriguez-Otero P, Villar S, Mejias L, Melero I, Prosper F, et al. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica. 2018;103:e318–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grabie N, Gotsman I, Dacosta R, Pang H, Stavrakis G, Butte MJ, et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 2007;116:2062–71.

Article  CAS  PubMed  Google Scholar 

Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, et al. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunol. 2017;6(12):e1361097. https://doi.org/10.1080/2162402X.2017.1361097.

Article  Google Scholar 

Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncol. 2018;23(8):879.

Article  Google Scholar 

Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2022;43(4):316–29.

Article  CAS  PubMed  Google Scholar 

Baban B, Liu JY, Qin X, Weintraub NL, Mozaffari MS, et al. Upregulation of programmed death-1 and its ligand in cardiac injury models: Interaction with GADD153. PloS One. 2015;10(4):e0124059.

Article  PubMed  PubMed Central  Google Scholar 

Kushnareva E, Kushnarev V, Artemyeva A, Mitrofanova L, Moiseeva O. Myocardial PD-L1 expression in patients with ischemic and non-ischemic heart failure. Front Cardiovasc Med. 2022;8:759972.

Article  PubMed  PubMed Central